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Objectives: to investigate the level of inflammatory markers between symptomatic and asymptomatic carotid stenosis
patients.
Design: cross-sectional study
Materials and methods: a prospective study of 137 consecutive patients, admitted electively for carotid endarterectomy
during 1997±2000, was conducted. 125 patients had cerebrovascular symptoms: either stroke (neurological deficit >24 h),
Transient ischaemic attack (neurological deficit524 h) or amaurosis fugax. Twelve patients were asymptomatic. A medical
history and a fasting venous blood sample were taken from each patient around 6 weeks before surgery. The plasma
concentrations of cholesterol and of inflammatory markers; (high sensitivity C-reactive protein (hs-CRP), sICAM-1,
sVCAM-1, sE-selectin) were determined.
Results: the concentration of hs-CRP in the symptomatic group (3.9 mg/L) was significantly higher than in the asymp-
tomatic group (2.1 mg/L; p 0.04). These concentrations were within normal range (510 mg/L). sICAM-1, sVCAM-1,
sE-selectin and total cholesterol concentrations were not different between the two groups.
Conclusion: plasma hs-CRP was elevated in symptomatic compared to asymptomatic patients with carotid artery disease.
High sensitivity C-reactive protein has been shown to be of prognostic value in a number of cardiovascular conditions and
this study suggests it may be of value to identify patient at high risk of developing neurological deficits.
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The Asymptomatic Carotid Artery Stenosis Trial
(ACAS) has shown the benefit of carotid endarterect-
omy (CEA) in preventing future strokes.1 The cost
effectiveness of this procedure is limited however.
As within 5 years only 1 stroke is prevented for
approximately 17 CEAs undertaken. In particular,
asymptomatic patients with diabetes mellitus and con-
tralateral siphon stenosis have a significantly higher
risk of perioperative stroke than other patients, so the
benefit of CEA in preventing strokes in this group is
marginal.2 A blood test, which could predict the risk of
a carotid atherosclerotic plaque leading to a stroke,
might be useful in identifying patients with asymp-
tomatic carotid stenosis, who have higher risk of
atheroembolism or haemodynamic insufficiency andPlease address all correspondence to: K. Rerkasem, Department
of Vascular Surgery, Level E West Wing, Southampton General
Hospital, Tremona Road, Southampton, SO16 6YD, U.K.
E-mail: kr4@soton.ac.uk
1078±5884/02/060505  05 $35.00/0 # 2002 Elsevier Science Ltd. Alis beneficial the most from surgery. No such studies
has been carried out before.
High sensitivity C-Reactive Protein (hs-CRP) has
been shown to be a predictive factor for cardiovascu-
lar events. Ridker et al. studied a large prospective
cohort study and found that high concentrations of
hs-CRP were associated with increased risk of stroke,
myocardial infarction and of developing symptomatic
peripheral vascular disease by 2, 3 and 4 fold, respect-
ively.3,4 In addition to hs-CRP, many other mediators
have been identified that can predict a cardiovascular
event, but from the head-to-head comparison study,
high hs-CRP concentration had a stronger relationship
with stroke and myocardial infarction than serum
amyloid A, soluble intercellular adhesion molecule-1
(sICAM-1), interleukin 6, total cholesterol, low density
lipoprotein (LDL) cholesterol, apolipoprotein A1,
Lp(a) lipoprotein and homocysteine.5 Interestingly,
few studies have explored the level of hs-CRP com-
pared to other inflammatory markers in patients with
symptomatic and asymptomatic carotid stenosis. Wel rights reserved.
Table 1. Clinical characteristics of the patients.
Variable Symptomatic
group
n 125
Asymptomatic
group
n 12
Median age (years) (range) 73 (45±85) 73 (56±78)
Body-mass index
(median; kg/m2) (range)
26 (19±43) 25 (19±31)
Gender: male (%) 78 (62) 7 (58)
Hypertension (%) 88 (70) 8 (67)
Diabetes mellitus (%) 25 (20) 2 (17)
Hypercholesterolaemia (%)
(Plasma cholesterol4
5 mmol/L)
36 (29) 7 (58)
Smoking
Former smoker (%) 81 (65) 9 (75)
Current smokers (%) 18 (14) 1 (8)
Non-smokers (%) 26 (21) 2 (17)
Angina pectoralis (%) 38 (30) 3 (25)
Previous myocardial
infarction (%)
11 (9) 2 (17)
Intermittent claudication (%) 33 (26) 4 (33)
Critical limb ischaemia (%) 0 0
Table 2. The degree of internal carotid artery stenosis and
medication between symptomatic and asymptomatic patients.
Variable Symptomatic
group
n 125
Asymptomatic
group
n 12
Ipsilateral ICA stenosis
Moderate (51±74%) 18 (14) 0
Severe (75±99%) 107 (86) 12 (100)
Contralateral ICA stenosis
Moderate (51±74%) (%) 15 (12) 3 (25)
Severe (75±99%) (%) 19 (15) 4 (33)
Lipid lowering drug
(Stain, fibrate) (%)
48 (38) 2 (17)
Aspirin (%) 113 (90) 12 (100)
Clopidrogrel (%) 3 (2) 0
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especially hs-CRP, in symptomatic patients with caro-
tid stenosis are elevated compared to asymptomatic
patients. If that is the case, it might lead to future
cohort studies to identify the mediators, which can
be used to select asymptomatic carotid stenosis
patients at high risk of developing neurological defi-
cits for surgery. The aims of this paper are to compare
the level of plasma inflammatory markers and total
cholesterol concentration between symptomatic and
asymptomatic carotid stenosis.
Methods
We prospectively included 137 consecutive patients
who were due for CEA. This was carried out in the
Department of Vascular Surgery, Southampton Gen-
eral Hospital, during 1997±2000. The indication for
surgery included symptomatic severe carotid stenosis
(>70%) and asymptomatic bilateral severe carotid
stenosis (>90%). The degree of stenosis of all patients
was assessed by duplex scan. There were 137 patients:
85 males and 52 females. The median age was 73 years
(range 45±85 years). Twelve patients were in the
asymptomatic group and 125 patients in the symp-
tomatic group. Patients were defined as asymptomatic
if they had never had any experience of neurological
deficit, either a transient ischaemic attack (TIA) or
stroke related to the affected vessel. Baseline clinical
data and cardiovascular events were evenly matched
in the two groups (Tables 1 and 2). In the symptomatic
group, the median duration between the last reported
symptom and venous blood sampling was 3 months.
A medical history was recorded and a physical
examination was undertaken. At the initial visit, fast-
ing venous blood was collected into vacutainer tubes
containing 0.12 ml of 15% EDTA. Plasma was prepared
by centrifugation at 1500 g for 10 min and stored at
ÿ80 C. Plasma hs-CRP was measured by an immuno-
turbidimetric technique using a commercially avail-
able kit, produced by Wako Laboratories and
available from Alpha Laboratories (Eastleigh, U.K.).
The technique had inter- and intra-assay coefficients
of variation of 6.4%, and 3.4%, respectively. Plasma
sICAM-1 and soluble vascular cell adhesion mol-
ecule-1 (sVCAM-1) concentrations were measured
using Cytoscreen ELISA kits from BioSource (Nivelles,
Belgium). Limits of detection were 0.04 ng/mL
(sICAM-1) and 0.5 ng/mL (sVCAM-1). Inter- and
intra-assay coefficients of variation were 55% for
both assays. Plasma soluble E-selectin (sE-selectin)
concentrations were measured using Quantikine
ELISA kits from R & D Systems Europe (Abingdon,Eur J Vasc Endovasc Surg Vol 23, June 2002U.K.). The limit of detection was 0.1 ng/mL, and inter-
and intra-assay coefficients of variation were 510%
and 55%, respectively. Plasma total cholesterol con-
centrations were measured using a commercially
available, enzyme-based diagnostic kit (Sigma Chem-
ical Co., Poole, U.K.).
Statistics
Since the data were not normally distributed, uni-
variate analysis was performed by the Mann±Whitney
U-test and Spearman's rank correlation test. Hs-CRP
concentration was logarithmically (ln) transformed
prior to multivariate analysis to obtain a normal dis-
tribution. Statistical analyses were performed using
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value for p less than 0.05 was considered as statis-
tically significant.
Results
The median concentration of hs-CRP among all
patients was 3.5 mg/L (range 0.2±84.9 mg/L). In uni-
variate analysis, the concentration of hs-CRP in the
symptomatic group was significantly higher than in
the asymptomatic group (Table 3). However, there
were no differences between these groups in terms of
the concentrations of sICAM-1, sVCAM-1, sE-selectin,
and total cholesterol. The median concentration of
hs-CRP in stroke patients (4.7 mg/L, range 0.5±
84.9 mg/L) was not significantly higher than in the
transient neurological deficit group (3.5 mg/L, range
0.2±36.9 mg/L) (p 0.36). No correlation was found
between hs-CRP concentration and the time delay
between onset of last symptoms and blood with-
drawal (r 0.08; p 0.33). The median concentration
of hs-CRP in males (3.7 mg/L, range 0.2±84.9) was not
significantly different compared with females
(3.5 mg/L, range 0.3±29.1) (p 0.81).
In multivariate analysis, the significant association
between hs-CRP concentration and symptoms
remained unaffected when adjusted for the duration
from the last event and became even more
pronounced when possible confounders were taken
into account (Table 4).Table 3. The comparison of concentration of inflammatory m
(median-range) (Mann±Whitney U-test).
Median concentration of
markers and range
Symptomatic group
n 125
hs-CRP (mg/L) 3.9 (0.2±84.9)
sICAM-1 (ng/mL) 323 (130±719)
sVCAM-1 (ng/mL) 616 (319±2192)
sE-selection (ng/mL) 43 (14±109)
Total cholesterol (mmol/L) 4.6 (3.0±11.0)
Table 4. Hs-CRP regression coefficients from multivariate regressio
various degrees of adjustment.
Adjustment Regression
coefficient
Standa
Errors
None 0.73 0.32
Duration since last event (months) 0.75 0.32
Possible confounders 0.84 0.33
Possible confoundersduration since last neurological event, age, sm
history of intermittent claudication or critical limb icchaemia, body
(plasma cholesterol5 5 mmol/L), history of diabetes mellitus.Discussion
This study shows that symptomatic patients with
severe carotid stenosis have elevated hs-CRP com-
pared with asymptomatic patients. This is the first
study to show the difference of the level of hs-CRP
between symptomatic and asymptomatic carotid sten-
osis. However this study cannot conclude that high
CRP level is the predictor of the progression of carotid
disease because it is a cross-sectional study. This issue
can only resolve with a large-scale cohort study. If that
is the case, hs-CRP may have a benefit in identifying
asymptomatic carotid stenosis patients at a higher risk
of neurological deficit. To confirm this benefit, a ran-
domised controlled trial should be carried out be-
tween surgical and medical treatment in the
asymptomatic patients with high level of hs-CRP.
The upper limit of normal of hs-CRP is 10 mg/L.12
The median level of hs-CRP in the carotid stenosis
patients both symptomatic and asymptomatic groups,
was within this (3.9 and 2.1 mg/L, respectively).
However, hs-CRP did not correlate with the severity
of the clinical condition (stroke, TIA) or with the
duration between the onset of the last neurological
symptom and sampling. This supports the findings
of Canova et al. who showed that CRP levels in
138 patients with acute neurological deficit was not
different between 5 clinical categories: transient is-
chaemic attack, reversible neurological deficit, com-
plete stroke and recovery, stroke without recovery
and cerebral haemorrhage.6 The concentration of
hs-CRP increases in response to acute ischaemia, likearkers between symptomatic and asymptomatic patients
Asymptomatic group
n 12
p value
2.1 (0.3±9.9) 0.04
337 (235±597) 0.66
582 (396±860) 0.44
44 (22±87) 0.44
5.3 (3.4±7.2) 0.08
n analysis of the presence of neurological dificit on in hs-CRP in
rd Lower 95%
confidence limit
Upper 95%
confidence limit
p value
0.10 1.36 0.02
0.12 1.38 0.02
0.18 1.50 0.01
oking status, history of angina pectoralis or myocardial infarction,
-mass index, gender, hypertension history, hypercholesterolaemia
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hs-CRP concentrations have been reported in many
conditions, such as cigarette consumption.8 Therefore,
cerebral ischaemic events and other factors (e.g. smok-
ing) are likely to be confounding variables in the
current study. However, the association between
symptoms and the concentration of hs-CRP remained
significant after adjusting for the duration since the
most recent neurological deficit (Table 4). Further-
more, the difference was still significant after adjust-
ing for the many possible confounding variables
including smoking status and the ischaemia of the
heart and the lower extremities.
A number of prospective studies have identified
peptide mediators such as other acute-phase
proteins, cytokines and soluble adhesion molecules
to be markers of cardiovascular disease.9±11 However,
hs-CRP appears superior than other markers: the
results of the current study and also from the large
cohort study in women show hs-CRP to be more
closely associated with cardiovascular events than
other markers.5 CRP is a very sensitive marker. The
plasma concentration of CRP can increase several
hundred fold following stimulation and is not effect-
ed by hormonal changes or anti-inflammatory
drugs.12,13 Furthermore, in contrast to many other
inflammatory markers, the assay techniques for hs-
CRP are highly sensitive and can detect even mild
elevation of CRP within the normal range.13 On
the whole, hs-CRP assay provides a simple and reli-
able measurement for the assessment of systemic
inflammation.
Although CEA has proved to be beneficial in
severe symptomatic carotid stenosis in two large
trials (ECST and NASCET), 8±10 CEAs are needed to
prevent one stroke over three years.14±16 Rothwell et al.
tried to increase the efficacy of surgical intervention
by developing a model that targeted patients, who
have a high chance of developing further
neurological events.17 Hs-CRP concentration after
stroke has been found to be a marker of increased
1 year risk in ischaemic stroke.18 If hs-CRP is able to
predict future neurological events in patients with
severe carotid stenosis in future cohort study, this
might improve targeting of surgery.
The mechanism of the association between raised
hs-CRP and cardiovascular symptoms is still uncer-
tain. The raised level of this inflammatory marker
may reflect an epi-phenomenon associated with the
atherosclerotic plaque, as some experimental studies
could identify CRP binding in the foamy macrophages
of atherosclerotic lesions.19 It has been hypothesised
that CRP might encourage lipid intake and cytolysis
of the atherosclerotic lesion, which will enlarge theEur J Vasc Endovasc Surg Vol 23, June 2002necrotic area in the lesion.19 An alternative hypothesis
is that raised hs-CRP concentrations might be related
to cardiovascular events via a causal pathway such as
increased thrombus formation, lipid oxidation, and
cell activation and proliferation.12 Tohgi et al. found
the activation of the coagulation/fibrinolysis system
and platelet function in patients with acute thrombotic
stroke with raised CRP.20
Limitations
As CRP level is usually elevated with injury or
inflammation including ischaemia or infection. Our
study took blood sampling after some of the pat-
ients has had symptoms, so the result might be con-
founded by the effect of cerebral ischaemia. Thus
a longitudinal study should be carried out. Although
we did not sample when patients were unwell from
any kind of obvious infection such as cold. This can-
not exclude infection. Erythrocyte sedimentation rate
(ESR) may be used to identify patients with inflam-
matory processes. Also our study potentially contains
selection bias. For example, there was a high propor-
tion of symptomatic cases (12 asymptomatic patients/
125 symptomatic patients), so our conclusions are
based on only 12 patients, resulting in a high chance
of a type 1 error. There was a high proportion of
bilateral severe asymptomatic carotid stenosis in
these 12 patients, because unilateral severe carotid
stenosis in asymptomatic patients is not a routine
indication of surgery in our unit.
Conclusion
Patients with symptomatic carotid stenosis have ele-
vated hs-CRP compared with asymptomatic patients.
This elevation of hs-CRP concentration is associated
with the presence of neurological events. The hs-CRP
level might be useful in selecting asymptomatic
carotid stenosis patients who will gain benefit from
CEA. A large prospective cohort study is necessary to
confirm and judge the clinical application of this
measurement.
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